SynVaccine develops preventive viral vaccines for various major human pathogens. It owns licenses for disruptive technologies that enable the computational rational design of viral genomes and physical DNA editing of viral vaccine genome libraries. Tuval Ben Yehezkel founded SynVaccine in 2013. It has its headquarters in Tel Aviv in Israel.

Health Care

Biotechnology

SynVaccine

Oren Bogin

Tal Almog

Modi Roopin

Tamir Tuller

The Leadership Team at SynVaccine, comprising the Interim CEO, VP of Synthetic Biology, and CSO, drives strategic direction, oversees R&D initiatives, and manages partnerships and regulatory compliance to advance the development and commercialization of preventive viral vaccines.

Leadership Team

About

Team members

Other teams at SynVaccine

Advisors Team